What is AMGN's 12-month price target and RQD AI Jury consensus?

AMGN's 12-month base price target is $496.87 (range $381.67 to $586.31), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / AMGN

GILD (83) MRNA (60) ARGX (64) RVMD (55) ⌘ Pro Terminal →

Amgen Inc. (AMGN) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell AMGN stock right now?

Amgen Inc. (AMGN) currently earns a Roarable Rating of B (Buy — BUY) with 73/100 RQD Confidence. High-quality cash engine (67.2% gross margin, 15% return on capital) with steady institutional support.

$465.45 -0.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $466.47

Amgen Inc. (AMGN) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (67.2% gross margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $251.94B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Amgen Inc. (NASDAQ: AMGN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $465.45 (-0.12% 1D, market cap $251.94B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 20/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, AMGN ranks #43 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMGN compare to GILD and MRNA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AMGN carries a Roarable B (73/100 RQD), trailing P/E of 32.3x, gross margin of 67.2%, and ROIC of 14.5%. By comparison, GILD (Gilead Sciences Inc.) holds a A- grade (83/100 RQD, P/E 24.1x, ROIC 21.0%, cap $211.64B) and MRNA (Moderna Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -34.1%, cap $88.52B). Among the 5-stock peer group, GILD leads on earnings multiple (24.1x) while GILD leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMGN?

▼

Per AMGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318154), Amgen Inc. generated $36.75B in revenue (+10.0% YoY), $7.71B in net income, and $8.10B in free cash flow against $90.59B in total assets and $50.01B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $466.47 (+0.22%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 22% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMGN)Realized 20D OHLCV Swing Band: ±5%

Deterministic 5-Pillar Attribution (73/100 Composite)

🔍 WHY AMGN SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+20/20 pts (27% of score)

20D Institutional Volume Accumulation (±5% realized swing band)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (69.2) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$426.11+2.9% Next Q

Q2 (-2Q)

Grade B-$438.34+3.1% Next Q

Q3 (-1Q)

Grade B$451.83+3% Next Q

Current

Grade B$465.45+7.1% Hist 90D α

Trajectory: C+ (65) → B (73)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AMGN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, AMGN faces multiple-compression risk if 32.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($421.21) or 200D SMA ($376.77) invalidates the momentum regime and cuts Target Base ($496.87) toward Bear Floor ($381.67).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 73%NO 27%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

69.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.83>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE94% OF RANGE

L: $292$465.45H: $476

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (67.2% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: ARQD 35 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on AMGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

14.5% ROIC with 67.2% gross margin and 3.25% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 3.83 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (77)

35/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like AMGN

✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMGN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.72%⚡ TESTING RESISTANCE

2026-11-03O $460.7H $466.0L $460.7C $465.5VOL 3.29M

RES: $477.5SUP: $399.5SMA50: $421.2SMA200: $376.8

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMGN Butterfly Map → + Track AMGN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.0%/yr Implied 5Y Growth

vs. +10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMGN)

Health Care Rank #43 of 1015 ⚔️ GILD vs AMGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMGN vs. GILD, MRNA, ARGX, RVMD)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Amgen Inc. (AMGN) ranks #43 by composite RQD confidence (73/100, grade B) and #9 by equity capitalization ($251.94B). Within this direct 5-issuer industry benchmark cohort, GILD leads on earnings valuation at 24.1x trailing P/E, while GILD leads on capital efficiency and profitability with 21.0% ROIC and 78.8% gross margin. GILD currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with AMGN at 73/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMGN ACTIVE Amgen Inc.	B	73/100	32.3x	67.2%	14.5%	-0.12%	$251.94B	Benchmark Subject
GILD Gilead Sciences Inc.	A-	83/100	24.1x	78.8%	21.0%	-0.20%	$211.64B	/gild-vs-amgn →
MRNA Moderna Inc.	C-	60/100	—	55.3%	-34.1%	-0.40%	$88.52B	/mrna-vs-amgn →
ARGX argenx SE	C	64/100	32.8x	—	9.9%	-2.00%	$55.41B	/argx-vs-amgn →
RVMD Revolution Medicines Inc.	D+	55/100	—	—	-28.6%	-1.64%	$41.00B	/rvmd-vs-amgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318154 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amgen Inc. (AMGN) reported GAAP revenue of $36.75B (+10.0% vs. FY2024 revenue of $33.42B , and +30.4% cumulative change since FY2023) , GAAP net income of $7.71B, operating cash flow of $9.96B, and free cash flow of $8.10B (-22.1% YoY). On the balance sheet, AMGN closed FY2025 with $90.59B in total assets against $50.01B in total debt (Altman Z-Score: 3.83, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$36.75B	$7.71B	$9.96B	$8.10B	$90.59B	$50.01B
FY2024 (FY)	2024-12-31	$33.42B	$4.09B	$11.49B	$10.39B	$91.84B	$56.55B
FY2023 (FY)	2023-12-31	$28.19B	$6.72B	$8.47B	$7.20B	$137.00B	$32.06B

3. AMGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AMGN compare to GILD and MRNA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AMGN?

Where is AMGN trading relative to its 50-day, 200-day, and 52-week technical levels?

AMGN last traded at $465.45 (-0.12% on volume of 3,196,520 shares), positioning the stock +10.50% above its 50-day simple moving average ($421.21) and +23.54% above its 200-day simple moving average ($376.77). Across its 52-week range of $292.12 to $475.65, AMGN sits at the 94.4% percentile with a 14-day RSI of 69.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($442.18 to $488.72).

Direct Sub-Reports: AMGN RQD Cockpit AMGN 12M Forecast AMGN Earnings & Move AMGN Dividends & DRIP AMGN Insiders & 13F AMGN Whale Options AMGN Profit Sankey AMGN News & Why

ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

AMGN — Amgen Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amgen Inc. (AMGN) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $465.45 (-0.12% 1D, market capitalization $251.94B).

Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 14.5%, gross margin of 67.2%, operating margin of 24.7%, and free cash flow yield of 3.25%.
Whale 13F & Options Flow (20/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (14/20): Incorporates a 0.87x equity beta, Altman Z-Score of 3.83, Piotroski F-Score of 8/9, and Debt/Equity of 5.78x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amgen Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the market data, the company reports a gross margin of 67.2%, an operating margin of 24.7%, and a net margin of 21%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amgen Inc. (AMGN) reported $36.75B in annual revenue (up from $33.42B in FY2024, +10.0% YoY) and $7.71B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.19B revenue, $6.72B net income) through FY2025, AMGN scaled operating cash flow to $9.96B and free cash flow to $8.10B, backed by $90.59B in total assets against $50.01B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 73/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 20/20, sustained execution supports upside toward the upper end of the $292.12 – $475.65 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.3x trailing P/E and 27.2x EV/EBITDA against 24.7% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain: NONE; butterfly links: none; proprietary signals: none.

Key Question #1: Can AMGN sustain or expand its 24.7% operating margin and 14.5% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $36.75B and free cash flow of $8.10B, how will capital allocation balance growth reinvestment against $50.01B in total debt?
Key Question #3: How sensitive is AMGN's 30.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

AMGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amgen Inc. (AMGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMGN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 23h ago

Amgen (AMGN) Laps the Stock Market: Here's Why

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

What Would It Take For Amgen Stock To Move Higher?

Trefis report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook

TradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers Unveiled

TradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMGN Bull vs. Bear Conversation Board — What's Your Call at $465.45?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMGN 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $591.83 (+27.0%)

📌 Pinned Debate

Whale 13F flow scores 19 / 20 in the RQD rating, signaling strong institutional accumulation alongside an Altman Z of 3.83 and a Piotro

Whale 13F flow scores 19 / 20 in the RQD rating, signaling strong institutional accumulation alongside an Altman Z of 3.83 and a Piotroski F of 8/9.. When you look under the hood at AMGN, Fundamental Cash Engine is 13/20 with 67.2% gross margins and 14.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (20/20) has been quietly accumulating below $475.65. My 12M target is $591.83.

VolSurface_Trader 🐂 BULL

@RiskArb_Desk Shorting a 20/20 institutional whale-flow stock at $466.01 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $368.15 (-21.0%)

Spot @ $466.01

A 32.3x trailing P/E, 27.2x EV/EBITDA, and a 3.25% FCF yield leave the valuation rich relative to cash generation, with Debt/Equity at

Fading this rally in AMGN at $466.01. A 32.3x trailing P/E, 27.2x EV/EBITDA, and a 3.25% FCF yield leave the valuation rich relative to cash generation, with Debt/Equity at 5.78.. With a beta of 0.87 and the stock sitting at $466.01 (52-wk range $294.48–$475.65), the easy multiple expansion is already priced in.